Maravai Lifesciences Holdings, Inc. (MRVI) — SEC Filings
Maravai Lifesciences Holdings, Inc. (MRVI) — 42 SEC filings. Latest: 10-Q (Nov 7, 2025). Includes 20 8-K, 8 SC 13G/A, 5 10-Q.
View Maravai Lifesciences Holdings, Inc. on SEC EDGAR
Overview
Maravai Lifesciences Holdings, Inc. (MRVI) is a publicly traded company tracked on ReadTheFiling. The most recent enriched filing is a 10-Q filed on Nov 7, 2025: Maravai LifeSciences Holdings, Inc. (MRVI) reported a significant decline in financial performance for the three and nine months ended September 30, 2025. Revenue decreased by 39.7% to $41.63 million for the three months ended September 30, 2025, from $69.03 million in the prior year, and by 32.9% t
Sentiment Summary
Across 42 filings, the sentiment breakdown is: 1 bullish, 2 bearish, 39 neutral. The dominant filing sentiment for Maravai Lifesciences Holdings, Inc. is neutral.
Filing Type Overview
Maravai Lifesciences Holdings, Inc. (MRVI) has filed 5 10-Q, 20 8-K, 2 DEF 14A, 2 10-K, 8 SC 13G/A, 5 SC 13G with the SEC between Jan 2024 to Nov 2025.
Filings by Year
Recent SEC Filings (42)
Risk Profile
Risk Assessment: Of MRVI's 29 recent filings, 2 were flagged as high-risk, 14 as medium-risk, and 13 as low-risk. The overall risk profile suggests moderate risk with a balanced mix of positive and cautionary disclosures.
Financial Highlights
| Metric | Value |
|---|---|
| Revenue | $41.63M |
| Net Income | $(45.06M) |
| Cash Position | $243.57M |
| Total Assets | $849.19M |
| Total Debt | $292.82M |
Key Executives
- Mr. Hull
- Mr. Martin
- Dr. David E. R. Gross
- Ms. Sarah E. Emrey
- Dr. Eric L. Johnson
- Mr. William D. Tempero
- Mr. Mark W. Wilson
- William R. Floyd
- Dr. Adina Kalush
- Dr. David R. Walt
- Dr. Paul J. Bolger
- Dr. William S. Merritt
- Dr. Robert J. Palladino
- William D. Tempero
Industry Context
The life sciences tools and services industry is characterized by innovation and demand driven by pharmaceutical and biotechnology R&D. Companies like Maravai operate in segments such as nucleic acid production and biologics safety testing, which are sensitive to overall healthcare spending and the pace of drug development. The competitive landscape requires continuous investment in technology and quality assurance to meet stringent regulatory standards.
Top Tags
financial-reporting (4) · sec-filing (4) · corporate-governance (4) · 8-K (4) · leadership-change (3) · executive-compensation (3) · 10-Q (3) · Biotechnology (2) · Life Sciences (2) · Earnings Miss (2)
Executive Compensation
From the most recent DEF 14A filing (Apr 25, 2024):
- Mr. Martin — Member
- Mr. Hull — Member
Key Numbers
| Metric | Value | Context |
|---|---|---|
| Revenue for Q3 2025 | $41.63M | Decreased by 39.7% from $69.03 million in Q3 2024 |
| Revenue for nine months ended Sep 30, 2025 | $135.88M | Decreased by 32.9% from $202.63 million in the same period of 2024 |
| Net loss for Q3 2025 | $(45.06M) | Improved from $(172.46M) in Q3 2024, largely due to lower goodwill impairment |
| Net loss for nine months ended Sep 30, 2025 | $(167.75M) | Improved from $(213.56M) in the same period of 2024 |
| Goodwill impairment for nine months ended Sep 30, 2025 | $42.88M | Significant operating expense, though lower than $154.24M in 2024 |
| Restructuring charge for Q3 and nine months ended Sep 30, 2025 | $7.39M | Indicates ongoing operational adjustments and costs |
| Cash and cash equivalents as of Sep 30, 2025 | $243.57M | Decreased from $322.40 million as of Dec 31, 2024 |
| Net cash used in operating activities for nine months ended Sep 30, 2025 | $(34.81M) | A shift from $22.10 million provided by operating activities in the same period of 2024 |
| Class A common shares outstanding as of Sep 30, 2025 | 144,718 | Increased from 141,976 shares as of Dec 31, 2024 |
| Q2 2025 Revenue | $68.5M | Down 36.7% from Q2 2024's $108.3M |
| Q2 2025 Net Income | $1.2M | Down 94% from Q2 2024's $20.1M |
| Six Months 2025 Revenue | $139.8M | Down 36.5% from prior year's $220.1M |
| Six Months 2025 Net Income | $4.1M | Down 89.9% from prior year's $40.5M |
| Q2 Revenue Decrease | 36.7% | Year-over-year decline in revenue for Q2 2025 |
| Acquisition Value | $3.4B | Total price GTCR is paying for Maravai. |
Forward-Looking Statements
- {"claim":"The updated filing might lead to minor short-term price fluctuations for Maravai LifeSciences Holdings, Inc. stock as investors digest the ownership details.","entity":"Maravai LifeSciences Holdings, Inc.","targetDate":"2024-02-15","confidence":"medium"}
Frequently Asked Questions
What are the latest SEC filings for Maravai Lifesciences Holdings, Inc. (MRVI)?
Maravai Lifesciences Holdings, Inc. has 42 recent SEC filings from Jan 2024 to Nov 2025, including 20 8-K, 8 SC 13G/A, 5 10-Q. Each filing includes an AI-generated plain-English summary.
What is the overall sentiment of MRVI filings?
Across 42 filings, the sentiment breakdown is: 1 bullish, 2 bearish, 39 neutral. The dominant sentiment is neutral.
Where can I find Maravai Lifesciences Holdings, Inc. SEC filings explained simply?
ReadTheFiling provides AI-powered plain-English summaries of all Maravai Lifesciences Holdings, Inc. (MRVI) SEC filings, including 10-K annual reports, 10-Q quarterly reports, 8-K current reports, and insider trades.
What are the key financial highlights for Maravai Lifesciences Holdings, Inc.?
Key financial highlights from Maravai Lifesciences Holdings, Inc.'s most recent 10-Q include metrics such as revenue, net income, EPS, and debt ratios. Visit the filing detail page for the full breakdown.
What is the investment thesis for MRVI?
The investment thesis for MRVI includes bull, base, and bear case scenarios derived from AI analysis of recent SEC filings.
Who are the key executives at Maravai Lifesciences Holdings, Inc.?
Key executives identified across Maravai Lifesciences Holdings, Inc.'s filings include Mr. Hull, Mr. Martin, Dr. David E. R. Gross, Ms. Sarah E. Emrey, Dr. Eric L. Johnson and 9 others.
What are the main risk factors for Maravai Lifesciences Holdings, Inc. stock?
Of MRVI's 29 assessed filings, 2 were flagged high-risk, 14 medium-risk, and 13 low-risk.
What are recent predictions and forward guidance from Maravai Lifesciences Holdings, Inc.?
Recent forward-looking statements from Maravai Lifesciences Holdings, Inc. include guidance on {"claim":"The updated filing might lead to minor short-term price fluctuations for Maravai LifeSciences Holdings, Inc. s.